Existing drugs boost new cancer vax responses FierceVaccines Researchers at the University of Pennsylvania are looking at using daclizumab (Zenapax)--a monoclonal antibody used to prevent transplant rejection--to target the Tregs and convert them into normal T cells, and to therefore restore the immune response ... |
